Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single Arm Phase II Clinical Trial of Recombinant Humanized Anti PD-1 Monoclonal Antibody and FOLFOXIRI Regimen Combined With Preoperative Intensity Modulated Radiation Therapy as the Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer

NCT06099951 is registered in ClinicalTrials.gov with Sun Yat-sen University as lead sponsor.

NCT NCT06099951
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06099951 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single Arm Phase II Clinical Trial of Recombinant Humanized Anti PD-1 Monoclonal Antibody and FOLFOXIRI Regimen Combined With Preoperative Intensity Modulated Radiation Therapy as the Total Neoadjuvant Treatment for pMMR Locally Advanced Low Rectal Cancer
Lead sponsor
Sun Yat-sen University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 1, 2023
Completion date
September 1, 2027
Enrollment
53 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer